By Chris Wack

CalciMedica shares were 82% lower, at 91 cents, after the company said it was discontinuing its Phase 2 clinical trial evaluating Auxora in patients with Stage 2 or Stage 3 acute kidney injury with associated acute hypoxemic respiratory failure.

The stock hit its 52-week low of 82 cents earlier in the session, and is down 66% in the past 12 months.

The clinical-stage biopharmaceutical company said the decision follows a recommendation from the trial's independent data monitoring committee.

During a prescheduled interim data review, the committee identified a safety concern that, in its view, warrants reevaluation of the study design, particularly with respect to patient enrollment criteria.

The company said that there were no deaths in the trial that were assessed by investigators or CalciMedica as being related to study drug, with either Auxora or a placebo. No serious adverse events met the criteria for expedited reporting to the Food and Drug Administration.

Based on the committee's recommendation, the company has discontinued the trial and plans to perform a comprehensive review of the unblinded clinical data.

CalciMedica notified the FDA about the trial discontinuation and will work with investigators to ensure all patients currently enrolled in the trial complete the full 90-day follow-up.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

January 28, 2026 10:09 ET (15:09 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.